Cellistem®IC is an allogeneic cell therapy based on the expansion of a subpopulation of umbilical cord tissue mesenchymal cells (MSCs), with unique characteristics for the treatment of Chronic Heart Failure (HF).

Infused intravenously in Chronic Heart Failure patients with reduced ejection fraction under optimal medical treatment.

It has been shown to produce a significant improvement in the left ventricular ejection fraction at 3, 6 and 12 months, associated with a significant increase in the expression of liver growth factor, known to be involved in myogenesis, cell migration and immunoregulation.

Published article from Randomized Controlled Clinical Trial I / II on Safety and Efficacy in the Top 5% of All Altmetric-Rated Research Results


Technology Readiness Level (TRL)